NASCENT BIOTECH, INC. (OTCMKTS:NBIO) Files An 8-K Regulation FD DisclosureITEM 7.01 FD Disclosure
On December 7, 2018 the Company received a letter from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for its human monoclonal antibody Pritumumab. The letter moves the Company’s application from a full clinical hold to a partial clinical hold, which allows the Company to begin Phase 1 clinical trials for brain cancers using its currently manufactured drug lot. Subject to the submission of additional data, the Company is of the understanding the partial clinical hold will be removed, giving full clearance of the IND.
About NASCENT BIOTECH, INC. (OTCMKTS:NBIO)
Nascent Biotech Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The Company is engaged in the research and development of the antibodies for control of brain and pancreatic cancer in humans. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company owns the license rights to a drug candidate, pritumumab, which it is developing. The Company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. Pritumumab is a monoclonal antibody. The Company has not generated revenues.
